Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival
Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The rel...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/186212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850120210712887296 |
|---|---|
| author | Amir Khammari Anne-Chantal Knol Jean-Michel Nguyen Céline Bossard Marc-Guillaume Denis Marie-Christine Pandolfino Gaëlle Quéreux Sylvain Bercegeay Brigitte Dréno |
| author_facet | Amir Khammari Anne-Chantal Knol Jean-Michel Nguyen Céline Bossard Marc-Guillaume Denis Marie-Christine Pandolfino Gaëlle Quéreux Sylvain Bercegeay Brigitte Dréno |
| author_sort | Amir Khammari |
| collection | DOAJ |
| description | Two first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P=0.023) or OS (P=0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression. |
| format | Article |
| id | doaj-art-68c98e8d0f654019869d06be4d6f543c |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-68c98e8d0f654019869d06be4d6f543c2025-08-20T02:35:25ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/186212186212Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient SurvivalAmir Khammari0Anne-Chantal Knol1Jean-Michel Nguyen2Céline Bossard3Marc-Guillaume Denis4Marie-Christine Pandolfino5Gaëlle Quéreux6Sylvain Bercegeay7Brigitte Dréno8Skin Cancer Unit, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, FranceCRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093 Nantes, FranceCRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093 Nantes, FranceService d’Anatomie et Cytologie Pathologiques, CHU Hôtel-Dieu, 30 boulevard Jean Monnet, 44093 Nantes, FrancePlateforme de Génétique des Cancers, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44000 Nantes, FranceCRCNA, INSERM U892, CNRS 6299, 9 Quai Moncousu, 44093 Nantes, FranceSkin Cancer Unit, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, FranceUnité de Thérapie Cellulaire et Génique (UTCG), CHU Hôtel-Dieu, 9 Quai Moncousu, 44093 Nantes, FranceSkin Cancer Unit, CHU Hôtel-Dieu, 1 Place Alexis Ricordeau, 44093 Nantes, FranceTwo first analyses of our clinical trial on TIL as adjuvant therapy for melanoma were published in 2002 and 2007. We present here an update of the clinical results after a 17-year median followup. In this trial, disease-free patients were randomly assigned to receive either TIL/IL-2 or IL-2. The relapse-free survival (RFS) was the primary objective. Eighty-eight patients were enrolled. A new analysis performed in May 2013 did not show significant changes in RFS or OS duration. However, our first finding on the association between the number of invaded lymph nodes and TIL effectiveness was strengthened. The Cox model adjusted on this interaction showed for the first time a significant treatment effect when considering the overall population, both on the RFS and OS. Patients treated with TIL had a longer RFS (P=0.023) or OS (P=0.020). This study being with a very long followup (17 years), confirmed the association between TIL effectiveness and the number of invaded lymph nodes, indicating that a low tumor burden could be a crucial factor enhancing the curative effect of TIL in possible microscopic residual disease. Moreover, we confirmed that a prolonged survival was associated with the presence of specific TIL and a decrease in Foxp3 expression.http://dx.doi.org/10.1155/2014/186212 |
| spellingShingle | Amir Khammari Anne-Chantal Knol Jean-Michel Nguyen Céline Bossard Marc-Guillaume Denis Marie-Christine Pandolfino Gaëlle Quéreux Sylvain Bercegeay Brigitte Dréno Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival Journal of Immunology Research |
| title | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
| title_full | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
| title_fullStr | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
| title_full_unstemmed | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
| title_short | Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival |
| title_sort | adoptive til transfer in the adjuvant setting for melanoma long term patient survival |
| url | http://dx.doi.org/10.1155/2014/186212 |
| work_keys_str_mv | AT amirkhammari adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT annechantalknol adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT jeanmichelnguyen adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT celinebossard adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT marcguillaumedenis adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT mariechristinepandolfino adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT gaellequereux adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT sylvainbercegeay adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival AT brigittedreno adoptivetiltransferintheadjuvantsettingformelanomalongtermpatientsurvival |